▶ 調査レポート

肺がん診断及び治療の世界市場 2020年:企業別、地域別、種類・用途別

• 英文タイトル:Global Lung Cancer Diagnosis and Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025

GlobalInfoResearchが調査・発行した産業分析レポートです。肺がん診断及び治療の世界市場 2020年:企業別、地域別、種類・用途別 / Global Lung Cancer Diagnosis and Therapeutics Market 2020 by Company, Regions, Type and Application, Forecast to 2025 / D005-00597資料のイメージです。• レポートコード:D005-00597
• 出版社/出版日:GlobalInfoResearch / 2020年5月29日
※2024年版があります。お問い合わせください。

• レポート形態:英文、PDF、121ページ
• 納品方法:Eメール
• 産業分類:医療・製薬
• 販売価格(消費税別)
  Single User¥522,000 (USD3,480)▷ お問い合わせ
  Multi User¥783,000 (USD5,220)▷ お問い合わせ
  Corporate User¥1,044,000 (USD6,960)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートでは、肺がん診断及び治療の世界市場を広く調査・分析し、今後の市場展望をまとめております。肺がん診断及び治療の種類別市場規模(非小細胞肺がん、小細胞肺がん)、用途別市場規模(病院、がん研究センター)、地域別市場規模(北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど)、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。
・市場概要
・企業情報(販売量、市場シェア、製品概要、SWOT分析):AstraZeneca、Pfizer、ArQule、Eli Lilly、Merck、Sanofi、Roche、Celgene、Daiichi Sankyo、Boehringer Ingelheim、Bayer、AbbVie、Genentech、Bristol-Myers Squibb、Novartis、GSK、Eisai、Pharmacyclics
・地域別グローバル市場分析 2015年-2020年
・肺がん診断及び治療の北米市場(アメリカ、カナダ、メキシコ)
・肺がん診断及び治療のヨーロッパ市場(ドイツ、イギリス、フランス、ロシア、イタリア)
・肺がん診断及び治療のアジア市場(中国、日本、韓国、インド、東南アジア、オーストラリア)
・肺がん診断及び治療の南米市場(ブラジル、アルゼンチン)
・肺がん診断及び治療の中東・アフリカ市場(サウジアラビア、トルコ、エジプト、南アフリカ)
・種類別分析:非小細胞肺がん、小細胞肺がん
・用途別分析:病院、がん研究センター
・地域別市場規模予測 2021年-2025年
・販売チャネル、流通業者、代理店
・調査の結果・結論

Market Overview
The global Lung Cancer Diagnosis and Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.

The Lung Cancer Diagnosis and Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentation
Lung Cancer Diagnosis and Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

By Type, Lung Cancer Diagnosis and Therapeutics market has been segmented into:
Non-Small Cell Lung Cancer
Small Cell Lung Cancer

By Application, Lung Cancer Diagnosis and Therapeutics has been segmented into:
Hospitals
Cancer Research Centers

Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Lung Cancer Diagnosis and Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Lung Cancer Diagnosis and Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Lung Cancer Diagnosis and Therapeutics market.

The report offers in-depth assessment of the growth and other aspects of the Lung Cancer Diagnosis and Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Competitive Landscape and Lung Cancer Diagnosis and Therapeutics Market Share Analysis
Lung Cancer Diagnosis and Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Lung Cancer Diagnosis and Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Lung Cancer Diagnosis and Therapeutics sales, revenue and market share for each player covered in this report.

The major players covered in Lung Cancer Diagnosis and Therapeutics are:
AstraZeneca
Pfizer
ArQule
Eli Lilly
Merck
Sanofi
Roche
Celgene
Daiichi Sankyo
Boehringer Ingelheim
Bayer
AbbVie
Genentech
Bristol-Myers Squibb
Novartis
GSK
Eisai
Pharmacyclics

レポート目次

Table of Contents

1 Lung Cancer Diagnosis and Therapeutics Market Overview
1.1 Product Overview and Scope of Lung Cancer Diagnosis and Therapeutics
1.2 Classification of Lung Cancer Diagnosis and Therapeutics by Type
1.2.1 Global Lung Cancer Diagnosis and Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Type in 2019
1.2.3 Non-Small Cell Lung Cancer
1.2.4 Small Cell Lung Cancer
1.3 Global Lung Cancer Diagnosis and Therapeutics Market by Application
1.3.1 Overview: Global Lung Cancer Diagnosis and Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Cancer Research Centers
1.4 Global Lung Cancer Diagnosis and Therapeutics Market by Regions
1.4.1 Global Lung Cancer Diagnosis and Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Lung Cancer Diagnosis and Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Lung Cancer Diagnosis and Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Lung Cancer Diagnosis and Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Lung Cancer Diagnosis and Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Lung Cancer Diagnosis and Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Lung Cancer Diagnosis and Therapeutics Status and Prospect (2015-2025)
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 AstraZeneca SWOT Analysis
2.1.4 AstraZeneca Product and Services
2.1.5 AstraZeneca Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Pfizer SWOT Analysis
2.2.4 Pfizer Product and Services
2.2.5 Pfizer Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 ArQule
2.3.1 ArQule Details
2.3.2 ArQule Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 ArQule SWOT Analysis
2.3.4 ArQule Product and Services
2.3.5 ArQule Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 Eli Lilly
2.4.1 Eli Lilly Details
2.4.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Eli Lilly SWOT Analysis
2.4.4 Eli Lilly Product and Services
2.4.5 Eli Lilly Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Merck
2.5.1 Merck Details
2.5.2 Merck Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Merck SWOT Analysis
2.5.4 Merck Product and Services
2.5.5 Merck Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.6 Sanofi
2.6.1 Sanofi Details
2.6.2 Sanofi Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Sanofi SWOT Analysis
2.6.4 Sanofi Product and Services
2.6.5 Sanofi Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.7 Roche
2.7.1 Roche Details
2.7.2 Roche Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 Roche SWOT Analysis
2.7.4 Roche Product and Services
2.7.5 Roche Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.8 Celgene
2.8.1 Celgene Details
2.8.2 Celgene Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Celgene SWOT Analysis
2.8.4 Celgene Product and Services
2.8.5 Celgene Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.9 Daiichi Sankyo
2.9.1 Daiichi Sankyo Details
2.9.2 Daiichi Sankyo Major Business and Total Revenue (Financial Highlights) Analysis
2.9.3 Daiichi Sankyo SWOT Analysis
2.9.4 Daiichi Sankyo Product and Services
2.9.5 Daiichi Sankyo Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.10 Boehringer Ingelheim
2.10.1 Boehringer Ingelheim Details
2.10.2 Boehringer Ingelheim Major Business and Total Revenue (Financial Highlights) Analysis
2.10.3 Boehringer Ingelheim SWOT Analysis
2.10.4 Boehringer Ingelheim Product and Services
2.10.5 Boehringer Ingelheim Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.11 Bayer
2.11.1 Bayer Details
2.11.2 Bayer Major Business and Total Revenue (Financial Highlights) Analysis
2.11.3 Bayer SWOT Analysis
2.11.4 Bayer Product and Services
2.11.5 Bayer Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.12 AbbVie
2.12.1 AbbVie Details
2.12.2 AbbVie Major Business and Total Revenue (Financial Highlights) Analysis
2.12.3 AbbVie SWOT Analysis
2.12.4 AbbVie Product and Services
2.12.5 AbbVie Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.13 Genentech
2.13.1 Genentech Details
2.13.2 Genentech Major Business and Total Revenue (Financial Highlights) Analysis
2.13.3 Genentech SWOT Analysis
2.13.4 Genentech Product and Services
2.13.5 Genentech Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.14 Bristol-Myers Squibb
2.14.1 Bristol-Myers Squibb Details
2.14.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.14.3 Bristol-Myers Squibb SWOT Analysis
2.14.4 Bristol-Myers Squibb Product and Services
2.14.5 Bristol-Myers Squibb Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.15 Novartis
2.15.1 Novartis Details
2.15.2 Novartis Major Business and Total Revenue (Financial Highlights) Analysis
2.15.3 Novartis SWOT Analysis
2.15.4 Novartis Product and Services
2.15.5 Novartis Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.16 GSK
2.16.1 GSK Details
2.16.2 GSK Major Business and Total Revenue (Financial Highlights) Analysis
2.16.3 GSK SWOT Analysis
2.16.4 GSK Product and Services
2.16.5 GSK Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.17 Eisai
2.17.1 Eisai Details
2.17.2 Eisai Major Business and Total Revenue (Financial Highlights) Analysis
2.17.3 Eisai SWOT Analysis
2.17.4 Eisai Product and Services
2.17.5 Eisai Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.18 Pharmacyclics
2.18.1 Pharmacyclics Details
2.18.2 Pharmacyclics Major Business and Total Revenue (Financial Highlights) Analysis
2.18.3 Pharmacyclics SWOT Analysis
2.18.4 Pharmacyclics Product and Services
2.18.3 Pharmacyclics Lung Cancer Diagnosis and Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Lung Cancer Diagnosis and Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Lung Cancer Diagnosis and Therapeutics Players Market Share
3.2.2 Top 10 Lung Cancer Diagnosis and Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Lung Cancer Diagnosis and Therapeutics Revenue and Market Share by Regions
4.2 North America Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Lung Cancer Diagnosis and Therapeutics Revenue by Countries
5.1 North America Lung Cancer Diagnosis and Therapeutics Revenue by Countries (2015-2020)
5.2 USA Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Lung Cancer Diagnosis and Therapeutics Revenue by Countries
6.1 Europe Lung Cancer Diagnosis and Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Revenue by Countries
7.1 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Revenue by Countries (2015-2020)
7.2 China Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Lung Cancer Diagnosis and Therapeutics Revenue by Countries
8.1 South America Lung Cancer Diagnosis and Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Lung Cancer Diagnosis and Therapeutics by Countries
9.1 Middle East & Africa Lung Cancer Diagnosis and Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Lung Cancer Diagnosis and Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Lung Cancer Diagnosis and Therapeutics Market Forecast by Type (2019-2024)
10.3 Non-Small Cell Lung Cancer Revenue Growth Rate (2015-2025)
10.4 Small Cell Lung Cancer Revenue Growth Rate (2015-2025)
11 Global Lung Cancer Diagnosis and Therapeutics Market Segment by Application
11.1 Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Lung Cancer Diagnosis and Therapeutics Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Cancer Research Centers Revenue Growth (2015-2020)
12 Global Lung Cancer Diagnosis and Therapeutics Market Size Forecast (2021-2025)
12.1 Global Lung Cancer Diagnosis and Therapeutics Market Size Forecast (2021-2025)
12.2 Global Lung Cancer Diagnosis and Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Lung Cancer Diagnosis and Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Lung Cancer Diagnosis and Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Lung Cancer Diagnosis and Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Lung Cancer Diagnosis and Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Lung Cancer Diagnosis and Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US

List of Tables

Table 1. Global Lung Cancer Diagnosis and Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Lung Cancer Diagnosis and Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Lung Cancer Diagnosis and Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Lung Cancer Diagnosis and Therapeutics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. AstraZeneca Corporate Information, Location and Competitors
Table 6. AstraZeneca Lung Cancer Diagnosis and Therapeutics Major Business
Table 7. AstraZeneca Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2017-2018)
Table 8. AstraZeneca SWOT Analysis
Table 9. AstraZeneca Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 10. AstraZeneca Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Pfizer Corporate Information, Location and Competitors
Table 12. Pfizer Lung Cancer Diagnosis and Therapeutics Major Business
Table 13. Pfizer Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2018-2019)
Table 14. Pfizer SWOT Analysis
Table 15. Pfizer Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 16. Pfizer Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. ArQule Corporate Information, Location and Competitors
Table 18. ArQule Lung Cancer Diagnosis and Therapeutics Major Business
Table 19. ArQule Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2017-2018)
Table 20. ArQule SWOT Analysis
Table 21. ArQule Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 22. ArQule Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Eli Lilly Corporate Information, Location and Competitors
Table 24. Eli Lilly Lung Cancer Diagnosis and Therapeutics Major Business
Table 25. Eli Lilly Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2017-2018)
Table 26. Eli Lilly SWOT Analysis
Table 27. Eli Lilly Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 28. Eli Lilly Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Merck Corporate Information, Location and Competitors
Table 30. Merck Lung Cancer Diagnosis and Therapeutics Major Business
Table 31. Merck Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2017-2018)
Table 32. Merck SWOT Analysis
Table 33. Merck Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 34. Merck Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. Sanofi Corporate Information, Location and Competitors
Table 36. Sanofi Lung Cancer Diagnosis and Therapeutics Major Business
Table 37. Sanofi Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2017-2018)
Table 38. Sanofi SWOT Analysis
Table 39. Sanofi Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 40. Sanofi Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. Roche Corporate Information, Location and Competitors
Table 42. Roche Lung Cancer Diagnosis and Therapeutics Major Business
Table 43. Roche Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2017-2018)
Table 44. Roche SWOT Analysis
Table 45. Roche Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 46. Roche Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Celgene Corporate Information, Location and Competitors
Table 48. Celgene Lung Cancer Diagnosis and Therapeutics Major Business
Table 49. Celgene Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2017-2018)
Table 50. Celgene SWOT Analysis
Table 51. Celgene Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 52. Celgene Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Daiichi Sankyo Corporate Information, Location and Competitors
Table 54. Daiichi Sankyo Lung Cancer Diagnosis and Therapeutics Major Business
Table 55. Daiichi Sankyo Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2017-2018)
Table 56. Daiichi Sankyo SWOT Analysis
Table 57. Daiichi Sankyo Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 58. Daiichi Sankyo Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 59. Boehringer Ingelheim Corporate Information, Location and Competitors
Table 60. Boehringer Ingelheim Lung Cancer Diagnosis and Therapeutics Major Business
Table 61. Boehringer Ingelheim Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2017-2018)
Table 62. Boehringer Ingelheim SWOT Analysis
Table 63. Boehringer Ingelheim Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 64. Boehringer Ingelheim Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 65. Bayer Corporate Information, Location and Competitors
Table 66. Bayer Lung Cancer Diagnosis and Therapeutics Major Business
Table 67. Bayer Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2017-2018)
Table 68. Bayer SWOT Analysis
Table 69. Bayer Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 70. Bayer Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 71. AbbVie Corporate Information, Location and Competitors
Table 72. AbbVie Lung Cancer Diagnosis and Therapeutics Major Business
Table 73. AbbVie Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2017-2018)
Table 74. AbbVie SWOT Analysis
Table 75. AbbVie Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 76. AbbVie Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 77. Genentech Corporate Information, Location and Competitors
Table 78. Genentech Lung Cancer Diagnosis and Therapeutics Major Business
Table 79. Genentech Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2017-2018)
Table 80. Genentech SWOT Analysis
Table 81. Genentech Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 82. Genentech Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 83. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 84. Bristol-Myers Squibb Lung Cancer Diagnosis and Therapeutics Major Business
Table 85. Bristol-Myers Squibb Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2017-2018)
Table 86. Bristol-Myers Squibb SWOT Analysis
Table 87. Bristol-Myers Squibb Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 88. Bristol-Myers Squibb Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 89. Novartis Corporate Information, Location and Competitors
Table 90. Novartis Lung Cancer Diagnosis and Therapeutics Major Business
Table 91. Novartis Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2017-2018)
Table 92. Novartis SWOT Analysis
Table 93. Novartis Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 94. Novartis Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 95. GSK Corporate Information, Location and Competitors
Table 96. GSK Lung Cancer Diagnosis and Therapeutics Major Business
Table 97. GSK Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2017-2018)
Table 98. GSK SWOT Analysis
Table 99. GSK Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 100. GSK Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 101. Eisai Corporate Information, Location and Competitors
Table 102. Eisai Lung Cancer Diagnosis and Therapeutics Major Business
Table 103. Eisai Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2017-2018)
Table 104. Eisai SWOT Analysis
Table 105. Eisai Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 106. Eisai Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 107. Pharmacyclics Lung Cancer Diagnosis and Therapeutics Type and Application
Table 108. Pharmacyclics Lung Cancer Diagnosis and Therapeutics Major Business
Table 109. Pharmacyclics Lung Cancer Diagnosis and Therapeutics Total Revenue (USD Million) (2017-2018)
Table 110. Pharmacyclics SWOT Analysis
Table 111. Pharmacyclics Lung Cancer Diagnosis and Therapeutics Product and Solutions
Table 112. Pharmacyclics Lung Cancer Diagnosis and Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 113. Global Lung Cancer Diagnosis and Therapeutics Revenue (Million USD) by Players (2015-2020)
Table 114. Global Lung Cancer Diagnosis and Therapeutics Revenue Share by Players (2015-2020)
Table 115. Global Lung Cancer Diagnosis and Therapeutics Revenue (Million USD) by Regions (2015-2020)
Table 116. Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Regions (2015-2020)
Table 117. North America Lung Cancer Diagnosis and Therapeutics Revenue by Countries (2015-2020)
Table 118. North America Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Countries (2015-2020)
Table 119. Europe Lung Cancer Diagnosis and Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 120. Asia-Pacific Lung Cancer Diagnosis and Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 121. South America Lung Cancer Diagnosis and Therapeutics Revenue by Countries (2015-2020)
Table 122. South America Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Countries (2015-2020)
Table 123. Middle East and Africa Lung Cancer Diagnosis and Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 124. Middle East and Africa Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Countries (2015-2020)
Table 125. Global Lung Cancer Diagnosis and Therapeutics Revenue (Million USD) by Type (2015-2020)
Table 126. Global Lung Cancer Diagnosis and Therapeutics Revenue Share by Type (2015-2020)
Table 127. Global Lung Cancer Diagnosis and Therapeutics Revenue Forecast by Type (2021-2025)
Table 128. Global Lung Cancer Diagnosis and Therapeutics Revenue by Application (2015-2020)
Table 129. Global Lung Cancer Diagnosis and Therapeutics Revenue Share by Application (2015-2020)
Table 130. Global Lung Cancer Diagnosis and Therapeutics Revenue Forecast by Application (2021-2025)
Table 131. Global Lung Cancer Diagnosis and Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Lung Cancer Diagnosis and Therapeutics Picture
Figure 2. Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Type in 2019
Figure 3. Non-Small Cell Lung Cancer Picture
Figure 4. Small Cell Lung Cancer Picture
Figure 5. Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Application in 2019
Figure 6. Hospitals Picture
Figure 7. Cancer Research Centers Picture
Figure 8. Global Lung Cancer Diagnosis and Therapeutics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 9. North America Lung Cancer Diagnosis and Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 10. Europe Lung Cancer Diagnosis and Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 11. Asia-Pacific Lung Cancer Diagnosis and Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. South America Lung Cancer Diagnosis and Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Middle East and Africa Lung Cancer Diagnosis and Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. Global Lung Cancer Diagnosis and Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Global Lung Cancer Diagnosis and Therapeutics Revenue Share by Players in 2019
Figure 16. Global Top 5 Players Lung Cancer Diagnosis and Therapeutics Revenue Market Share in 2019
Figure 17. Global Top 10 Players Lung Cancer Diagnosis and Therapeutics Revenue Market Share in 2019
Figure 18. Key Players Market Share Trend
Figure 19. Global Lung Cancer Diagnosis and Therapeutics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 20. Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 21. Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Regions in 2018
Figure 22. North America Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 23. Europe Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 24. Asia-Pacific Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 25. South America Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 26. Middle East and Africa Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 27. North America Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 28. North America Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Countries in 2019
Figure 29. USA Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 30. Canada Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 31. Mexico Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 32. Europe Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 33. Europe Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Countries in 2019
Figure 34. Germany Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 35. UK Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 36. France Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 37. Russia Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 38. Italy Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 39. Asia-Pacific Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 40. Asia-Pacific Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Countries in 2019
Figure 41. China Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 42. Japan Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 43. Korea Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 44. India Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 45. Southeast Asia Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 46. South America Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 47. South America Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Countries in 2019
Figure 48. Brazil Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 49. Argentina Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 50. Middle East and Africa Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 51. Middle East and Africa Lung Cancer Diagnosis and Therapeutics Revenue Market Share by Countries in 2019
Figure 52. Saudi Arabia Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 53. UAE Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 54. Egypt Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 55. South Africa Lung Cancer Diagnosis and Therapeutics Revenue and Growth Rate (2015-2020)
Figure 56. Global Lung Cancer Diagnosis and Therapeutics Revenue Share by Type (2015-2020)
Figure 57. Global Lung Cancer Diagnosis and Therapeutics Revenue Share by Type in 2019
Figure 58. Global Lung Cancer Diagnosis and Therapeutics Market Share Forecast by Type (2021-2025)
Figure 59. Global Non-Small Cell Lung Cancer Revenue Growth Rate (2015-2020)
Figure 60. Global Small Cell Lung Cancer Revenue Growth Rate (2015-2020)
Figure 61. Global Lung Cancer Diagnosis and Therapeutics Revenue Share by Application (2015-2020)
Figure 62. Global Lung Cancer Diagnosis and Therapeutics Revenue Share by Application in 2019
Figure 63. Global Lung Cancer Diagnosis and Therapeutics Market Share Forecast by Application (2021-2025)
Figure 64. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 65. Global Cancer Research Centers Revenue Growth Rate (2015-2020)
Figure 66. Global Lung Cancer Diagnosis and Therapeutics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 67. Global Lung Cancer Diagnosis and Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 68. Global Lung Cancer Diagnosis and Therapeutics Revenue Market Share Forecast by Regions (2021-2025)
Figure 69. North America Lung Cancer Diagnosis and Therapeutics Revenue Market Forecast (2021-2025)
Figure 70. Europe Lung Cancer Diagnosis and Therapeutics Revenue Market Forecast (2021-2025)
Figure 71. Asia-Pacific Lung Cancer Diagnosis and Therapeutics Revenue Market Forecast (2021-2025)
Figure 72. South America Lung Cancer Diagnosis and Therapeutics Revenue Market Forecast (2021-2025)
Figure 73. Middle East and Africa Lung Cancer Diagnosis and Therapeutics Revenue Market Forecast (2021-2025)
Figure 74. Sales Channel: Direct Channel vs Indirect Channel